STOCK TITAN

iTeos Therapeutics, Inc. - $ITOS STOCK NEWS

Welcome to our dedicated page for iTeos Therapeutics news (Ticker: $ITOS), a resource for investors and traders seeking the latest updates and insights on iTeos Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iTeos Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iTeos Therapeutics's position in the market.

Rhea-AI Summary
iTeos Therapeutics, Inc. presented preclinical data on EOS-984, a small molecule inhibitor targeting ENT1 at AACR Annual Meeting. EOS-984 showed potential in enhancing T cell function and tumor cell killing, synergizing with anti-PD-1 therapy in triple negative breast cancer. Phase 1 trial results are expected in late 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary
iTeos Therapeutics, Inc. appointed Jill DeSimone to its Board of Directors, bringing over 40 years of global business expertise in life sciences. DeSimone's experience includes significant roles at Merck & Co., Inc. and Teva Pharmaceutical Industries, Ltd. Her appointment aims to enhance iTeos' strategic direction in immuno-oncology therapeutics development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
management
-
Rhea-AI Summary
iTeos Therapeutics, Inc. (ITOS) reports financial results for Q4 and full year 2023, highlighting upcoming clinical milestones, cash position, and key appointments. The company anticipates a transformative year in 2024 with multiple Phase 2 trials and preclinical presentations. They aim to leverage their strong cash balance and robust pipeline to deliver on anticipated milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
Rhea-AI Summary
iTeos Therapeutics, Inc. (ITOS) presented preclinical data on EOS-984, a novel immuno-oncology therapeutic at the AACR Annual Meeting. The poster showcased the potential of a first-in-class small molecule antagonist targeting equilibrative nucleoside transporter 1 (ENT1) to alleviate immune suppression caused by intracellular adenosine. The presentation took place on April 7, 2024, in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
-
Rhea-AI Summary
iTeos Therapeutics, Inc. (ITOS) will participate in two investor conferences in March 2024, including Cowen 44th Annual Healthcare Conference and Leerink Partners Global Biopharma Conference. The company aims to showcase its immuno-oncology therapeutics for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.23%
Tags
conferences
-
Rhea-AI Summary
iTeos Therapeutics, Inc. (Nasdaq: ITOS) anticipates significant clinical data readouts in 2024 for their TIGIT and Adenosine portfolio, with a cash balance of $644.9 million providing runway through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
none
Rhea-AI Summary
iTeos Therapeutics, Inc. (Nasdaq: ITOS) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
conferences
-
Rhea-AI Summary
iTeos Therapeutics, Inc. (ITOS) will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York City on November 28, 2023. The company focuses on immune-oncology therapeutics for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
conferences
-
Rhea-AI Summary
iTeos Therapeutics, Inc. reported financial results for Q3 2023, including a cash balance of $644.9 million, completion of enrollment in several clinical trials, and plans for future data readouts in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
Rhea-AI Summary
iTeos Therapeutics, Inc. (Nasdaq: ITOS) to participate in two investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
conferences
iTeos Therapeutics, Inc.

Nasdaq:ITOS

ITOS Rankings

ITOS Stock Data

413.24M
24.79M
0.54%
102.4%
5.71%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
WATERTOWN

About ITOS

starting operations in 2012, iteos therapeutics is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by developing immunotherapies by design. iteos is developing eos200271, a clinical-stage potent and selective ido1 inhibitor with exceptional brain penetration. the company is also advancing eos100850, an insurmountable and non-brain penetrant adenosine a2a receptor antagonist, into a phase 1 trial in the second half of 2018; and a human adcc-enabling anti-tigit antibody (eos884448), representing an additional, third clinical entry in 2019. based in gosselies, belgium, iteos therapeutics was founded and supported in part by investments from the ludwig institute cancer research (licr), the walloon region of belgium and the european fund for economic and regional development (feder). for more information, please visit www.iteostherapeutics.com.